Insider Buying: MGC Pharmaceuticals Limited (ASX:MXC) Insider Acquires A$18,852.46 in Stock

MGC Pharmaceuticals Limited (ASX:MXCGet Rating) insider Roby Zomer purchased 819,672 shares of the stock in a transaction on Friday, May 6th. The shares were bought at an average price of A$0.02 ($0.02) per share, for a total transaction of A$18,852.46 ($13,091.98).

The company has a current ratio of 1.87, a quick ratio of 1.50 and a debt-to-equity ratio of 23.87.

MGC Pharmaceuticals Company Profile (Get Rating)

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia.

Recommended Stories

Receive News & Ratings for MGC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MGC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.